Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short-term Investments (2016 - 2025)

Tg Therapeutics has reported Short-term Investments over the past 10 years, most recently at $62.8 million for Q4 2025.

  • Quarterly results put Short-term Investments at $62.8 million for Q4 2025, down 52.08% from a year ago — trailing twelve months through Dec 2025 was $62.8 million (down 52.08% YoY), and the annual figure for FY2025 was $62.8 million, down 52.08%.
  • Short-term Investments for Q4 2025 was $62.8 million at Tg Therapeutics, up from $57.5 million in the prior quarter.
  • Over the last five years, Short-term Investments for TGTX hit a ceiling of $145.2 million in Q3 2024 and a floor of $15.9 million in Q4 2021.
  • Median Short-term Investments over the past 5 years was $64.5 million (2022), compared with a mean of $81.2 million.
  • Biggest five-year swings in Short-term Investments: plummeted 69.46% in 2021 and later soared 273.99% in 2022.
  • Tg Therapeutics' Short-term Investments stood at $15.9 million in 2021, then soared by 273.99% to $59.4 million in 2022, then skyrocketed by 109.81% to $124.6 million in 2023, then grew by 5.24% to $131.1 million in 2024, then plummeted by 52.08% to $62.8 million in 2025.
  • The last three reported values for Short-term Investments were $62.8 million (Q4 2025), $57.5 million (Q3 2025), and $122.7 million (Q2 2025) per Business Quant data.